These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 18356456

  • 21. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS, Sheller A.
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [Abstract] [Full Text] [Related]

  • 22. Nephrogenic systemic fibrosis: is gadolinium the missing piece to the puzzle?
    Bennett LK, Garrett AL.
    Cutis; 2008 May; 81(5):421-6. PubMed ID: 18543594
    [Abstract] [Full Text] [Related]

  • 23. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M, Boateng F, Patel SS, Masood SF, Mahajan P, Patel N, Murray B.
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS, Sanyal S, Abraham JL.
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [Abstract] [Full Text] [Related]

  • 28. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN.
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
    Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA.
    AJR Am J Roentgenol; 2007 Feb; 188(2):586-92. PubMed ID: 17242272
    [Abstract] [Full Text] [Related]

  • 35. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS.
    J Comput Assist Tomogr; 2009 Feb; 33(6):819-23. PubMed ID: 19940643
    [Abstract] [Full Text] [Related]

  • 36. Safety of older generations of gadolinium in mild-to-moderate renal failure.
    Khatami SM, Mahmoodian M, Zare E, Pashang M.
    Ren Fail; 2012 Feb; 34(2):176-80. PubMed ID: 22260266
    [Abstract] [Full Text] [Related]

  • 37. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB, Maize JC, Woolson RF, Budisavljevic MN.
    Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.
    High WA, Ayers RA, Chandler J, Zito G, Cowper SE.
    J Am Acad Dermatol; 2007 Jan; 56(1):21-6. PubMed ID: 17097388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.